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Summary The 28-item GHQ was used to assess psychiatric morbidity in 302 women attending for routine
breast cancer screening, 300 women attending for further investigation of a positive screening result and 150
women referred for investigation of breast symptoms. The GHQ-28 was administered on arrival at the relevant
clinic and three months later. Medical records were used to determine the outcome of the clinic attendance.
Women were classified into routinely screened women, women with false positive screening results, symp-
tomatic women with a benign diagnosis, newly diagnosed cancer patients and previously treated cancer
patients. When tested on arrival at the clinic, 25% of routinely screened, 30% of women with false positive
results and 35% of symptomatic women with benign conditions were probable cases of psychiatric morbidity.
The only statistically significant difference was between the routinely screened and symptomatic benign groups.
Levels of anxiety were significantly higher in those with false positive results and in the symptomatic benign
group than in the routinely screened. Three months later the prevalence of probable psychiatric morbidity had
fallen to 19% in both the routinely screened and those with false positive results but remained significantly
higher in the symptomatic benign group (31%). Probable cases of psychiatric morbidity among newly detected
cancer patients rose from 34 to 46% over the 3-month period. Among women who had had breast cancer
diagnosed in the past prevalence remained at 21%. The prevalence of probable psychiatric morbidity in
screened women is similar to that in the general population. Among women referred for further investigation
because of a false positive screening result prevalence was only slightly increased and there was no evidence of
a sustained increase in anxiety. Provided that delays are kept to a minimum and that women are kept
informed, a breast cancer screening programme does not increase psychiatric morbidity. Further research is
required in cancer patients to determine whether those diagnosed in asymptomatic women have a higher and
more sustained degree of psychiatric morbidity than those diagnosed in women who are aware of symptoms.
Concern has been expressed that screening for breast cancer
may have adverse psychological effects. The invitation for
screening may make women more aware of their vulnera-
bility and hence increase anxiety. Recalling women who are
found to have an abnormality on screening for further inves-
tigation (currently 5-10% of those screened in the UK) may
cause distress which is hard to alleviate even when further
investigations are negative. Those who are symptom-free on
screening but are found to have cancer could find it es-
pecially hard to adapt to the diagnosis (Maguire, 1982).
The first concern has been partially investigated in Edin-
burgh (Dean et al., 1986). It was found that women atten-
ding for screening had no excess psychiatric morbidity com-
pared to other women in the same age-group, (although little
is yet known about morbidity in those who did not attend in
response to invitation). Our study set out to investigate
immediate and persistent psychiatric morbidity in those refer-
red for further investigation because of an abnormal screen-
ing result, and to compare these women with attenders for
screening and with women being investigated for breast can-
cer because of symptoms.
Methods
As part of the UK Trial of Early Detection of Breast Cancer
(1981), over the past 8 years women aged 45-71 registered
with general practitioners in South-West Surrey Health Dist-
rict have been invited for annual breast cancer screening. The
attendance rate at the time of this study was 65% overall and
73% among those being invited for the first time either
because they had just reached 45 years or because they had
recently moved into the district. An earlier study (Calnan,
1985) investigated reasons for non-attendance in this screen-
ing programme. Those found to have a suspicious screening
result are recalled to a review clinic for further investigation.
Between March 1985 and June 1986 five consecutive atten-
ders for routine screening and five consecutive attenders at
the review clinic were recruited each week for this study.
Similarly, women in the same age-group referred to an out-
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patient clinic for investigation of breast symptoms were in-
cluded. Eighty-two per cent of the women recruited at the
screening clinic and 80% of those recruited at review clinics
had been screened in previous years.
On arrival at the relevant clinic, before seeing the doctor
or undergoing mammography, each woman was asked by a
research nurse to complete the 28-item version of the General
Health Questionnaire (Goldberg, 1978). A condition placed
on the psychological study was that it should not reduce
compliance or interfere with the efficiency of the main trial
screening programme. The GHQ-28 is brief and acceptable
and, using score >4, provides a valid measure of com-
parison between groups when the object is to detect anxiety
or depression of fairly recent onset. Three months later, the
same women were again asked to complete the GHQ-28 and
then to answer questions about their clinic experiences (these
will be discussed more fully in a separate paper). The 3-
month repeat questionnaire was administered at home by a
research nurse to all women with a score of five or more on
the initial GHQ-28, and to 60% of those with lower scores.
The remaining 40% who scored low on the initial GHQ-28
were sent the repeat questionnaire by post.
Clinical records were used to determine the outcome of
each woman's attendance. The women have been categorised
as follows: (A) attenders at screening in whom no abnor-
mality was found; (B) review clinic attenders whose further
investigation showed no cancer (false positives); (C) symp-
tomatic women whose investigation showed no cancer; (D)
symptomatic or review clinic women in whom breast cancer
was diagnosed in this episode; (E) women with a past history
of breast cancer returning for screening of the opposite
breast or because of new symptoms. The GHQ-28 scores
were compared between these five groups, using a score of
five or more to distinguish those who were probable cases of
psychiatric morbidity from those who were not and using the
X2 test with Yates' correction to test for statistical signifi-
cance.
The GHQ scores were further analysed by non-parametric
methods as the distributions are grossly skewed. The Wil-
coxon matched pairs signed rank test was used to test the
significance of changes in scores between the first and second
questionnaires, and the Mann-Whitney U test for com-
parison of scores between groups. P values are based on
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two-tailed tests and results are considered significant if P is
less than 0.05.
Results
Out of 774 women approached 10 were excluded from ana-
lyses because they were interviewed at a routine screening
attendance but were subsequently recalled for further inves-
tigation. Ofthe remaining women 752 (98.4%) agreed to take
part and, of these, 733 (97.5%) completed both the question-
naires. The distribution of women in the five groups is shown
in Table I.
GHQ-28 scores at clinic attendance
The prevalence of scores of five and over was greatest in the
symptomatic benign abnormality (35%) and the newly detec-
ted cancer (34%) groups, intermediate in the false positive
group (30%), and least in women attending for routine
screening (25%) and in past treated cancer patients (21%)
(Table II). In comparing one group against another, with a
threshold score of five the only statistically significant differ-
ence was between the routinely screened group and the group
with symptomatic benign abnormalities (X2 = 5.44, P<0.02).
Among the routinely screened, 17 out of 54 (31%) women
attending for the first time had scores of five or more,
compared with 56 out of 241 (23%) in those who had
attended previously (X2= 1.2, n.s.).
The GHQ-28 provides scores on four sub-scales; anxiety,
depression, somatic symptoms and social dysfunction.
Women in the false positive and symptomatic benign abnor-
mality groups had significantly greater anxiety scores than
those attending for routine screening (P<0.02 and <0.002
respectively, Mann-Whitney U test). Other differences were
not significant.
GHQ-28 scores 3 months later
Three months after the relevant clinic attendance the preva-
lence of scores of five or more had fallen significantly to the
Table I Characteristics of study subjects
Group D, Group E,
Group A, Group B, Group C, Newly Previously
routinely screened: symptomatic detected treated
screened false + ve benign cancer cancer
Total recruited 295 271 134 38 14
No. comp- 287 266 129 37 14
leting both (97.3%) (98.2%) (96.3%) (97.4%) (100%)
GHQs
Mean age 53.9 54.5 52.8 58.1 54.8
(± s.d.) ± 6.8) (± 7.4) (±7.0) (±7.1) (±5.5)
First screening 18.3% 20.7%
episode
same level, 19% in both the routinely screened group and in
the false positive group (P values for falls <0.05 and
<0.005 respectively) (Table III). Scores were still raised in
the symptomatic benign abnormality group (31%). The pre-
valence was unchanged in the previously treated cancer
group (21%) and had risen to 46% in the group with newly
detected cancer. Scores in the latter three groups were
significantly higher than in the routinely screened group,
(Table III). Nine of the 18 patients with new cancer diag-
nosed by screening asymptomatic women had scores of five
or more.
Changes in score were the same for those low initial
scorers who were sent postal questionnaires as for those
visited (Mann-Whitney U test, P = 0.7, n.s.). The 3-month
GHQ-28 scores for the routinely screened and false positive
groups did not differ significantly between women attending
screening for the first time and those who had been screened
in the past.
When analysed by the component scales of the GHQ-28,
scores on the anxiety scale had fallen significantly in the false
positive group (P<0.0001). Within the new cancer patient
group there were significant increases in the somatic symp-
toms scale (P<0.001) and the social dysfunction scale
(P<0.0001).
Table IV and Table II further illustrate the similarity
between the false positive and routinely screened groups on
the second occasion with 3% more of the false positives
having anxiety symptoms but 8% fewer having somatic symp-
toms and 7% more having total scores of zero.
Table III Prevalence ofGHQ scores offive or more at time ofclinic
visit and 3 months later
Prevalence (95% CI)
At time ofclinic visit 3 months later
A, routinely screened 24.0% (20-30%) 19.2% (15-24%)
B, screened: false positive 30.1% (24-36%) 18.8% (14-24%)
C, symptomatic benign 35.7% (24-44%) 31.0% (23-39%)
D, newly detected cancer 35.1% (20-51%) 45.9% (30-63%)
E, previously treated cancer 21.4% ( 5-51%) 21.4% ( 5-51%)
Significance ofdifferences
x2 p x2 p
A versus B 2.34 n.s. 0.00 n.s.
A versus C 5.44 0.02 6.43 0.01
A versus D 1.59 n.s. 12.09 0.005
A versus E - n.s. - n.s.
B versus C 0.33 n.s. 6.68 0.01
The 19 women who failed to complete the second GHQ are excluded
from this table; this explains the slight difference in prevalance at clinic
visit from Table II.
Table 11 Distribution of general health questionnaire scores
At clinic attendance
Group A Group B Group C Group D Group E
No. % No. % No. % No. % No. %
Ist GHQ score
Zero score 118 40.0 111 41.0 45 33.6 13 34.2 7 50.0
Score 1-4 104 35.3 78 28.8 42 31.3 12 31.6 4 28.6
Score 5-9 49 16.6 48 17.7 26 19.4 9 23.7 2 14.3
Score 10-28 24 8.1 34 12.5 21 15.7 4 10.5 1 7.1
Total 295 100% 271 100% 134 100% 38 100% 14 100%
2nd GHQ score 3 months later
Zero score 150 52.3 157 59.0 53 41.1 8 21.6 9 64.3
Score 1-4 82 28.6 59 22.2 36 27.9 12 32.4 2 14.3
Score 5-9 31 10.8 23 8.6 21 16.3 9 24.3 1 7.1
Score 10-28 24 8.4 27 10.2 19 14.7 8 21.6 2 14.2
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Table IV Distribution of subscale scoring (no. and percentage ofwomen who scored one or more points)
Group A Group B Group C Group D Group E
3 months 3 months 3 months 3 months 3 months
Symptoms Clinic later Clinic later Clinic later Clinic later Clinic later
subscale (n = 295) (n = 287) (n = 271) (n = 266) (n = 134) (n = 129) (n = 38) (n = 37) (n = 14) (n = 14)
Somatic 113 (38%) 98 (34%) 108 (40%) 69 (26%) 59 (44%) 55 (43%) 17 (45%) 23 (62%) 5 (36%) 4 (29%)
Anxiety 104 (35%) 75 (26%) 119 (44%) 77 (29%) 67 (50%) 49 (38%) 16 (42%) 15 (41%) 6 (43%) 5 (36%)
Social dysfunction 104 (35%) 86 (30%) 89 (33%) 77 (29%) 50 (37%) 48 (37%) 18 (47%) 25 (68%) 5 (36%) 3 (21%)
Depression 42 (14%) 29 (10%) 38 (14%) 27 (10%) 21 (16%) 21 (16%) 4 (11%) 5 (14%) 1 ( 7%) 1 ( 7%)
Biopsied women
Six women in the false positive group and 11 in the symp-
tomatic benign abnormality group had to undergo excision
biopsy as a hospital inpatient in order to exclude the diag-
nosis of cancer. Despite the fact that the need for biopsy was
unknown at the time of completing the first questionnaires,
in both groups their first questionnaire scores were high, 10
(59%) having scores of five or over. Three months later 6/16
(37.5%) still scored five or over.
Opinions about clinic attendance and subsequent management
The main way in which women felt that anxiety could be
reduced in the clinics was by shortening all periods of
waiting. Women in the false positive group usually had to
wait less than a week for their review clinic appointments
and most were discharged after a single review clinic atten-
dance, whereas those referred to hospital outpatient clinics
with a benign abnormality had to wait longer for an appoint-
ment, wait longer at the clinic, and more often had to return
for a further visit.
Forty (7%) out of 553 women in the routinely screened
and false positive groups criticised some aspects of com-
munication at the clinic, compared with 18 out of 129 (14%)
in the group with symptomatic benign abnormalities. Despite
the fact that all the cancer patients knew their diagnosis, 15
out of 51 (29%) were critical of some aspect of communica-
tion, including one who complained of being told more than
she wanted to know.
Thirteen (5%) out of 253 questioned about the screening
examination complained of embarrassment during examina-
tion and mammography.
Discussion
The prevalence of scores of five or more, indicating probable
psychiatric morbidity, among women attending for routine
screening is in the middle of the range reported in other
community-based studies of women in this age range (Wil-
liams et al., 1986). This adds weight to the conclusion of the
Edinburgh study (Dean et al., 1986) that attendance for
screening does not increase psychiatric morbidity.
The prevalence of probable psychiatric morbidity among
women in the false positive group was slightly, but not
significantly, higher than in those attending for routine
screening. But anxiety symptoms were - not surpris-
ingly - more common, and a few women admitted to
experiencing panic while waiting for their review clinic
appointment. However, the GHQ-28 at 3 months showed no
lasting increase in anxiety or in psychiatric morbidity as a
whole. This is reassuring in that one of the worries expressed
about the current screening programme is that the anxiety
induced in these women with false positive results outweighs
the benefit of prolongation of life for some cancer patients
(Wright, 1986).
An underlying reason for this concern may be the exper-
ience that many clinicians have in managing women with
symptomatic benign abnormalities. These women showed a
prevalence of probable psychiatric morbidity higher than
either the routinely screened or the false positive groups, but
similar to that found in studies of women attending GP
surgeries (Finlay-Jones & Burvill, 1978). Moreover, their
raised prevalence of high GHQ-28 scores persisted for 3
months, even after a diagnosis of breast cancer had been
ruled out. These women may well belong to a group who
present underlying psychological distress somatically.
Those with newly diagnosed cancer are a small but impor-
tant group. Asymptomatic women attending for screening
probably believe they are free of cancer and the unexpected
news that they have cancer may be harder to assimilate than
in women warned of the possibility of cancer by their symp-
toms. Moreover, they may also worry because they have no
confidence that any recurrence will manifest itself by symp-
toms. But the number of breast cancers in this study is too
small to make a valid comparison between the screen-detec-
ted cases and the symptomatic cases. A larger study is needed
to assess whether the method of breast cancer detection
affects the degree and duration of psychiatric morbidity.
This study indicates that breast cancer screening need not
lead to any sustained increase in the prevalence of psychiatric
morbidity in a community. The study was, however, con-
ducted in a well-established screening programme and one in
which clinical examination was included. First attenders
showed slightly more anxiety than others at the time of
screening but were insufficient in number for firm conclusions
to be drawn. The effect on psychological morbidity of int-
roducing the national mammographic screening programme
should be monitored to ensure that it too is minimal. The
comments of screened women indicate the importance of
minimising delays in the diagnostic process and of maintain-
ing full and frank communication throughout.
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